Using DCLK1-IN-1, the Gray [17], Westover [18], and Buchert [31] groups demonstrated several functional properties of DCLK1 inhibition in pancreatic, colorectal, and gastric cancers, respectively. This evidence concerns the gene DCLK1 and gastric cancer.